GF FUND MANAGEMENT CO. LTD.
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 2057060
GUANGZHOU, F4
Position in ALNY
as of Mar 31, 2026
· filed Apr 15, 2026
Position Value
$9,939,665
-$2,173,549 QoQ
Shares Held
30,041
-1.4% QoQ
Ownership
0.023%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GF FUND MANAGEMENT CO. LTD. holds $82,416,104 across 208 Biotechnology names. ALNY ranks #3 (12.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
64,591 | $28,842,465 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
28,281 | $21,851,031 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
30,041 | $9,939,665 | |
| 4 | INSM |
INSMED Inc
|
48,496 | $7,930,065 | |
| 5 | INCY |
Incyte Corp
|
8,742 | $822,797 | |
| 6 | ARGX |
Argenx SE
|
653 | $476,853 | |
| 7 | RPRX |
Royalty Pharma plc
|
9,596 | $460,320 | |
| 8 | MRNA |
Moderna, Inc.
|
8,775 | $445,770 |
All Filings in ALNY
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,939,665 | 30,041 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $12,113,214 | 30,462 | Shares | Sole | 2026-01-27 | |
| 2025-09-30 | $1,275,432 | 2,797 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $1,076,749 | 3,302 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $891,606 | 3,302 | Shares | Sole | 2025-04-29 | |
| 2024-12-31 | $637,219 | 2,708 | Shares | Sole | 2025-02-19 | |
| No filing history on record for this holder in this stock. | ||||||